BR9808077A - Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente - Google Patents

Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente

Info

Publication number
BR9808077A
BR9808077A BR9808077-6A BR9808077A BR9808077A BR 9808077 A BR9808077 A BR 9808077A BR 9808077 A BR9808077 A BR 9808077A BR 9808077 A BR9808077 A BR 9808077A
Authority
BR
Brazil
Prior art keywords
mirtazapine
animal
combination
antipsychotic agent
pharmaceutical formulation
Prior art date
Application number
BR9808077-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Christophorus Louis Broekkamp
Hermanus Henricus Ge Berendsen
Roger Martin Pinder
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9808077A publication Critical patent/BR9808077A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9808077-6A 1997-03-27 1998-03-25 Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente BR9808077A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97202785 1997-09-11
PCT/EP1998/001920 WO1998043646A1 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Publications (1)

Publication Number Publication Date
BR9808077A true BR9808077A (pt) 2000-03-08

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808077-6A BR9808077A (pt) 1997-03-27 1998-03-25 Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente

Country Status (24)

Country Link
EP (1) EP0969845B1 (https=)
JP (2) JP4377456B2 (https=)
KR (1) KR100577865B1 (https=)
CN (1) CN1226036C (https=)
AR (1) AR012193A1 (https=)
AT (1) ATE318604T1 (https=)
AU (1) AU726194B2 (https=)
BR (1) BR9808077A (https=)
CA (1) CA2284551C (https=)
CZ (1) CZ298105B6 (https=)
DE (1) DE69833645T2 (https=)
DK (1) DK0969845T3 (https=)
ES (1) ES2259207T3 (https=)
HU (1) HUP0002742A3 (https=)
ID (1) ID22283A (https=)
IL (1) IL123716A (https=)
NO (1) NO994673L (https=)
NZ (1) NZ337618A (https=)
PL (1) PL191449B1 (https=)
PT (1) PT969845E (https=)
RU (1) RU2222330C2 (https=)
TR (1) TR199902334T2 (https=)
TW (1) TW587938B (https=)
WO (1) WO1998043646A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
AU780817B2 (en) * 2000-01-19 2005-04-21 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US7304047B2 (en) 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
RU2232574C2 (ru) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН Лекарственное средство для лечения различных форм депрессий "флуоглизин"
ES2405404T3 (es) 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
SI1541197T1 (sl) * 2003-12-02 2009-08-31 Pharmaneuroboost N V Uporaba pipamperona in sndri, snri ali ssri za zdravljenje razpoloĺ˝enjskih ali tesnobnih motenj
EP1708790B1 (en) 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
AU2007255724B2 (en) * 2006-06-09 2012-05-10 Dainippon Sumitomo Pharma Co., Ltd. Novel tape preparation
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
DE102012011839B4 (de) * 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
DK0431663T3 (da) * 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
FI111367B (fi) * 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (ru) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Способ лечения эндогенных психозов
DE69327542T2 (de) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Also Published As

Publication number Publication date
CN1251526A (zh) 2000-04-26
EP0969845B1 (en) 2006-03-01
HK1023293A1 (en) 2000-09-08
PT969845E (pt) 2006-05-31
CN1226036C (zh) 2005-11-09
DE69833645T2 (de) 2006-08-24
TW587938B (en) 2004-05-21
IL123716A0 (en) 1998-12-06
IL123716A (en) 2001-03-19
TR199902334T2 (xx) 2000-01-21
KR100577865B1 (ko) 2006-05-10
CZ298105B6 (cs) 2007-06-27
NZ337618A (en) 2000-06-23
HUP0002742A3 (en) 2003-03-28
NO994673L (no) 1999-11-17
DK0969845T3 (da) 2006-06-19
PL335890A1 (en) 2000-05-22
AU726194B2 (en) 2000-11-02
JP2009280596A (ja) 2009-12-03
JP2001521497A (ja) 2001-11-06
JP4377456B2 (ja) 2009-12-02
ID22283A (id) 1999-09-30
ATE318604T1 (de) 2006-03-15
HUP0002742A2 (hu) 2001-05-28
ES2259207T3 (es) 2006-09-16
AU7213998A (en) 1998-10-22
KR20010005677A (ko) 2001-01-15
CA2284551C (en) 2007-06-12
JP5023315B2 (ja) 2012-09-12
NO994673D0 (no) 1999-09-24
WO1998043646A1 (en) 1998-10-08
CA2284551A1 (en) 1998-10-08
RU2222330C2 (ru) 2004-01-27
PL191449B1 (pl) 2006-05-31
DE69833645D1 (de) 2006-04-27
CZ343199A3 (cs) 2000-04-12
AR012193A1 (es) 2000-09-27
EP0969845A1 (en) 2000-01-12

Similar Documents

Publication Publication Date Title
BR9808077A (pt) Combinação, formulação farmacêutica, processo para o tratamento de um distúrbio psicótico em um aninal, usos de mirtazapina e de um agente antipsicótico, e, pacote para paciente
BR9814106A (pt) Processo para tratar da esquizofrenia em um indivìduo, e, conjunto
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
BR0210941A (pt) Terapia de combinação de oxazolidinonas substituìdas
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
ATE203675T1 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
BR9913585A (pt) Formulação de toxina botulinum farmacêutica lìquida estável, método de tratar um paciente em necessidade de inibição de entrada colinérgica em um músculo selecionado, grupo de músculos, glândula ou órgão, e, uso de uma formulação de toxina botulinum lìquida estável
BRPI0110914B8 (pt) 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
BR9810773A (pt) Uso de um ingrediente anestésico local de ação prolongada, composição farmacêutica, uso de um anestésico local, e, kit
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
PT1001775E (pt) Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
BR9713681A (pt) Artigo absorvente para ser utilizado por um usuário adjacente à pele
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
NO801387L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive morfantridin-derivater
PA8471801A1 (es) Derivados de higromicina a
PT90816A (pt) Processo para a preparacao de composicoes farmaceuticas contendo analogos de 2',5'-oligoadenilato
FI101849B1 (fi) Antimikrobiset koostumukset ja niiden käyttö silmälääkkeiden säilömiseksi ja piilolinssien hoitamiseksi
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements